Review of traditional Chinese medicine against polycythemia vera

ZOU Jixuan; HU Xiaomei

doi:10.16025/j.1674-1307.2024.10.003

您当前的位置：

首页 >

文章列表页 >

Review of traditional Chinese medicine against polycythemia vera

更新时间：2024-11-26

- Review of traditional Chinese medicine against polycythemia vera
- Beijing Journal of Traditional Chinese Medicine Vol. 43, Issue 10, Pages: 1092-1096(2024)
- 作者机构：
  
  1.北京中医药大学西苑临床医学院100091
  2.中国中医科学院西苑医院血液科100091
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2024.10.003
  CLC：
- Published：25 October 2024，
  
  Received：18 June 2024，
- 稿件说明：
移动端阅览
邹吉轩，胡晓梅.中医药治疗真性红细胞增多症研究进展［J］.北京中医药，2024，43（10）：1092-1096.

ZOU Jixuan,HU Xiaomei.Review of traditional Chinese medicine against polycythemia vera[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(10):1092-1096.
邹吉轩，胡晓梅.中医药治疗真性红细胞增多症研究进展［J］.北京中医药，2024，43（10）：1092-1096. DOI： 10.16025/j.1674-1307.2024.10.003.

ZOU Jixuan,HU Xiaomei.Review of traditional Chinese medicine against polycythemia vera[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(10):1092-1096. DOI： 10.16025/j.1674-1307.2024.10.003.

摘要

热、毒、瘀是真性红细胞增多症（PV）的主要病理因素，清热解毒、活血化瘀是治疗PV的主要治法。中医药治疗能够减轻高凝状态、改善证候以及降低JAK2突变负荷等，中西药联合应用可以显著提高临床疗效。中医药治疗PV疗效机制与其改善骨髓微环境、促进肿瘤细胞凋亡有关。中药复方中的多种单体相互协调，共同作用于多条通路、多个靶点，共同发挥作用。多中心大样本RCTs将有利于获得证据级别较高的循证医学依据，多组学技术将有助于深入探索中药复方多重效应和相互作用的复杂机制。

Abstract

关键词

真性红细胞增多症中医药疗效机制中药复方

Keywords

references

ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016,127(20):2391-405.

SROUR SA,DEVESA SS,MORTON LM,et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States,2001-12[J].Br J Haematol,2016,174(3):382-396.

BARBUI T,THIELE J,GISSLINGER H,et al.The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms:document summary and in-depth discussion[J]. Blood Cancer J,2018,8(2):15.

TEFFERI A,RUMI E,FINAZZI G,et al.Survival and prognosis among 1 545 patients with contemporary polycythemia vera: an international study[J].Leukemia,2013,27(9):1874-1881.

SZUBER N,MUDIREDDY M,NICOLOSI M,et al.3023 Mayo clinic patients with myeloproliferative neoplasms:risk-stratified comparison of survival and outcomes data among disease subgroups[J].Mayo Clin Proc,2019,94(4):599-610.

CERQUOZZI S,BARRACO D,LASHO T,et al.Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients[J]. Blood Cancer J, 2017,7(12):662. Published 2017 Dec 27.

中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国指南（2022年版）[J]. 中华血液学杂志,2022,43(7):537-541.

ALVAREZ-LARRÁN A,PEREIRA A,CERVANTES F,et al.Assessment and prognostic value of the European Leukemia Net criteria for clinicohematologic response,resistance,and intolerance to hydroxyurea in polycythemia vera[J].Blood,2012,119(6):1363-1369.

JENTSCH-ULLRICH K,EBERHARDT J,et al.Characteristics and treatment of polycythemia vera patients in clinical practice:a multicenter chart review on 1476 individuals in Germany[J]. J Cancer Res Clin Oncol, 2016, 142(9) : 2041-2049.

DEMUYNCK T, VERHOEF G, DELFORGE M, et al. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis[J].Ann Hematol,2019,98(6):1421-1426.

ALVAREZ-LARRÁN A,KERGUELEN A,HERNÁNDEZ-BOLUDA JC,et al.Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera[J].Br J Haematol, 2016,172(5) : 786-793.

ALVAREZ-LARRÁN A,PÉREZ-ENCINAS M,FERRER-MARÍN F,et al.Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea[J].Haematologica,2017,102(1):103-109.

BEWERSDORF JP,GIRI S,WANG R,et al.Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis[J]. Leukemia, 2021,35(6):1643-1660.

VAINCHENKER W, KRALOVICS R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms[J]. Blood, 2017,129(6):667-679.

REGIMBEAU M,MARY R,HERMETET F,et al.Genetic background of polycythemia vera[J].Genes(Basel),2022,13(4):637.

HASSELBALCH HC.Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis.A human inflammation model for cancer development[J].Leuk Res,2013,37(2):214-220.

KORN C, MÉNDEZ-FERRER S.Myeloid malignancies and the microenvironment[J].Blood,2017,129(7):811-822.

CHEN Y, ZHU J, LUM PY, et al. Variations in DNA elucidate molecular networks that cause disease[J]. Nature, 2008,452(7186):429-435.

温晓文,徐斌. 周郁鸿治疗真性红细胞增多症之经验[J]. 江苏中医药,2017,49(1):22-24.

陈贝贝,张杰. 李秀荣治疗真性红细胞增多症的经验[J]. 现代中医药,2015,35(5):7-8.

赖宗浪,史雯,马薇,等.李冬云运用理气活血法治疗骨髓增殖性肿瘤的临床经验[J].北京中医药,2014,33(4):263-266.

李慧,代喜平,李达. 梁冰中医辨治真性红细胞增多症经验[J]. 中华中医药杂志,2018,33(11):5008-5011.

肖海燕,方苏,胡晓梅,等. 邓成珊论治真性红细胞增多症经验撷英[J].上海中医药杂志,2014,48(2):1-3.

雍彦礼,鲍玉玺,赵齐,等. 基于《黄帝内经》“血实宜决之”探讨真性红细胞增多症的中医证治[J]. 云南中医中药杂志,2023,44(2):98-101.

张伟锋,杨文华,王兴丽,等. 杨文华教授治疗真性红细胞增多症经验荟萃[C]//中华中医药学会第二届岐黄论坛:血液病中医药防治分论坛论文集.2014:1-4.

王丽,刘宝文. 刘宝文教授辨证治疗真性红细胞增多症[J]. 实用中医内科杂志,2012,26(6):21-22.

张明辉,王秀娟,张丽娜,等.从肝论治真性红细胞增多症[J].北京中医药,2021,40(10):1110-1111.

明静,李芋锦,杨二鹏,等.基于数据挖掘及网络药理学探讨胡晓梅主任治疗真性红细胞增多症的用药规律及机制[J].天津中医药,2021,11:1463-1471.

白洁,石慧,艾丽梅,等.单中心真性红细胞增多症816例生存现状及预后分析[J].中华医学杂志,2015,95(18):1364-1368.

王巍.红花黄色素配合羟基脲治疗真性红细胞增多症40例临床分析[J].长春中医药大学学报,2010,26(6):884.

臧奉娇,王树庆,王念德,等.活血通脉颗粒对真性红细胞增多症患者血栓弹力图K值的影响[J].安徽中医药大学学报,2017,36(2):22-25.

吴庆,潘铭,黄建霞,等.中西医结合治疗真性红细胞增多症的疗效观察[J].中医临床研究,2021,13(31):98-100.

臧奉娇,王树庆,王念德,等.脉血康胶囊联合羟基脲片治疗真性红细胞增多症临床研究[J].医学信息,2017,30(1):60-61.

TEFFERI A,LASHO TL,GUGLIELMELLI P,et al.Targeted deep sequencing in polycythemia vera and essential thrombocythemia[J].Blood Adv,2016,1(1):21-30.

KLEPPE M,KWAK M,KOPPIKAR P,et al.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response[J].Cancer Discov,2015,5(3):316-331.

PASSAMONTI F,RUMI E,PIETRA D,et al.Relation between JAK2(V617F) mutation status, granulocyte activation,and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders[J].Blood,2006,107(9):3676-3682.

VANNUCCHI AM,ANTONIOLI E,GUGLIELMELLI P,et al.Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:a critical reappraisal[J].Leukemia，2008;22(7):1299-1307.

张兰红.疏肝活血汤治疗PV患者的临床疗效观察及雄黄对HEL细胞株的影响[D].济南:山东中医药大学,2012.

王玉慧.斑蝥素对HEL细胞株JAK2基因表达的影响研究及复方斑蝥胶囊治疗真性红细胞增多症临床疗效观察[D].济南:山东中医药大学,2012.

刘存.青黄散联合羟基脲干预骨髓增殖性肿瘤的临床疗效观察及对JAK2V617F的影响[D].济南:山东中医药大学,2019.

邓来军,董杨,王翠,等.大黄䗪虫丸治疗JAK2-V617F阳性真性红细胞增多症的临床研究[J].南京中医药大学学报,2020,36(6):820-825.

LI R,ZHOU Y,CAO Z,et al.Tet 2 loss dysregulates the behavior of bone marrow mesenchymal stromal cells and accelerates Tet 2-/--driven myeloid malignancy progression[J]. Stem Cell Reports, 2018,10(1):166-179.

LIU X,XU N,PAN C,et al.Emerging potential roles of lysyl-oxidase-like 2 stimulates cancer associated fibroblasts promoting myelofibrosis of myeloproliferative neoplasms[J].Blood,2016,128(22):5495.

CHILDS BG,BAKER DJ,KIRKLAND JL,et al.Senescence and apoptosis: dueling or complementary cell fates[J].EMBO Rep,2014,15(11):1139-1153.

ALAM M, ALAM S, SHAMSI A, et al.Bax/Bcl-2 cascade is regulated by the EGFR pathway:therapeutic targeting of non-small cell lung cancer[J].Front Oncol,2022,12:869672.

刘基铎,何惠,周迎春,等.瘀毒清诱导真性红细胞增多症原代细胞凋亡的研究[J].广东医学,2012,33(9):1218-1220.

马怀安,熊丽丽,张长军,等.活血化瘀法对真性红细胞增多症CD34+细胞凋亡的影响[J].中国中医基础医学杂志,2007(6):447-448.

杨洪涌,孙金芳,陈志雄,等.活血祛瘀法对真性红细胞增多症细胞凋亡及相关基因表达的影响[J].中药新药与临床药理,2004(3):208-211.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathogenesis and treatment of bronchiectasis based on “healthy qi depletion leading to accumulation and injury” theory

PIAO Bingkui's experience in differentiating and treating colorectal cancer based on the concept of “harmony and integration”

Differentiation of syndrome and treatment of “long COVID-19” syndrome based on the theory of Zongqi

GAO Yanbin's experience in the treatment of diabetic peripheral neuropathy with a pair of herbal drugs from the perspective of collaterals

Effect of Shugan Lidan Jianpi Recipe on high risk patients with poor biochemical response to primary cholangitis

Related Author

ZHANG Jinzhi

FAN Yiling

YUAN Shasha

KONG Jinli

LI Rui

WEI Yuchen

MIAO Qing

ZHANG Xiyuan

Related Institution

中国中医科学院西苑医院呼吸科

北京中医药大学

中国中医科学院广安门医院国际医疗部

中国中医科学院广安门医院

中国中医科学院广安门医院南区呼吸科

⁰